Since the landmark Control & Complications Trial (DCCT) in the early 90's we've all known that add up and tight glycemic hold back are improved through frequent daub glucose testing and aggroup management with a knowledgeable remote caregiver. Unfortunately today's blood glucose meters lack the connectivity to aid this remote teaming interaction. The result is millions of people left to bring home the bacon their diabetes in isolation especially the newly diagnosed. change surface with all of the increased sales of diabetes testing supplies blood sugar hold back and physician adherence to established standards of compassionate worldwide remain unacceptable by every diabetes organization worldwide including the American Diabetes Association. American Association of Clinical Endocrinologists. American Association of Diabetes Educators and the International Diabetes Federation. Direct costs of diabetes compassionate in the USA undergo more than doubled in recent years according to the Centers for Disease Control & Prevention. "Without any practical means of enjoying the benefits of aggroup management costs from the current paradigm of test and drop self-care ordain bankrupt our global economy," says Kevin McMahon. President & CEO of Diabetech. Clinical inefficiencies also originate in from this lack of connectivity further driving up costs. Even the recently introduced continuous glucose monitoring devices are not capable of supporting communication with knowledgeable remote caregivers. Diabetech offers a better say to patients and the healthcare industry when it comes to an effective model for diabetes compassionate including control for spiralling costs. Diabetech's GlucoMON blood glucose connectivity device ensures glucose meter accuracy and automates the collection and analysis of blood glucose data for use in the team management of diabetes. populate typically inform drops in their add up blood glucose (haemoglobin A1c) levels from 10% - 30% when they use a GlucoMON and change surface more in some cases. Advanced technology simplifying the affect is the key. As Stephen Ponder. MD CDE and Diabetech's Chief Medical Officer likes to say. 'Diabetech makes improvements to self-care and remote patient interventions ridiculously easy'. Representatives from health plans self-insured employers and individual participants and their families involved in our various Institutional Review Board approved research trials have been providing feedback culminating in support for the development of a new commercial version of the GlucoMON upgraded for the global market. Based on interim clinical trial results from GlucoMON-enabled intervention programs payers are already acknowledging a clear path to their Return On Investment (ROI); a pivotal metric that has been difficult for generalist disease management firms to show. GlucoMON2 is approximately 80% smaller than the previous GlucoMON making it the smallest and lightest GlucoMON ever. GlucoMON2 also makes the world's easiest way to overlap blood glucose levels even easier with even more automation designed into the device itself. GlucoMON2 availability is planned for Q3 '2007 and is capable of operating anywhere in the world where there is support for GSM/GPRS networks. The bundled device airtime and function ordain be available through payer-sponsored and direct- to-consumer programs. Not only is GlucoMON2 more advanced; it's also more personalized with a variety of designer colors available based on local preferences. Companies interested in distribution and/or establishing programs leveraging GlucoMON2 should contact Diabetech immediately for more information. Previous generation GlucoMONs have generated over 70 patient-years of device usability and safety data. The original GlucoMON broke new fasten in December of 2002 supporting the first end-to-end wireless diabetes management system in the world connecting patients and their extended compassionate teams in real-time. To this day. Diabetech remains the only provider anywhere offering a comprehensive solution encompassing the glucose measure supplies long-range wireless management device wireless network transport remote control stored patient records and active informatics including trend identification and feedback - all under one cover. Our current GlucoMON supports LifeScan®'s Ultra® glucose measure across many clinical trials throughout North America and will act in its role as a research device. Prior to the open of the Ultra®2. Diabetech had been evaluating usability of newer glucose meters as candidates for GlucoMON2 integration. We arrived at our decision to support the Ultra2 as the first glucose measure integration to our GlucoMON2 mobile telemetry platform due to its broad patient adoption unsurpassed quality and the fact that its OneTouch® blood glucose evaluate strips are the most widely reimbursed strip on the merchandise. Likewise we selected GSM/GPRS as our wireless network backbone due to its broad global footprint and give for high speed data applications in.
Related article:
http://levitranow.blogspot.com/2007/08/diabetech-to-transform-global-diabetes.html
comments | Add comment | Report as Spam
|
